Back to Sectors

BCLI

BRAINSTORM CELL THERAPEUTICS INC.
4 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 80% | 3/31/2026 | regulatory actionBEARISH | 90% | 3/31/2026 | capital raiseNEUTRAL | 40% | 3/31/2026 | management changeBULLISH | 60% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | regulatory actionBEARISH | 90% | 5/15/2026 | dilution riskBULLISH | 60% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | regulatory actionBEARISH | 90% | 5/15/2026 | dilution riskBULLISH | 70% | 5/28/2026 | management changeBEARISH | 30% | 5/28/2026 | dilution riskMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 28

Appointment of former FDA Associate Commissioner to the board enhances regulatory credibility.

management change
70%
bearishMay 28

Issuance of 150,000 share options to a new director increases potential share dilution.

dilution risk
30%
bullishMay 15

Net loss reduced by 26% year-over-year through aggressive cost cutting in R&D and G&A.

margin expansion
60%
neutralMay 15

Raised $1.25 million in Q1 2026 via private placements and short-term loans to sustain operations.

capital raise
50%
bullishMay 15

FDA granted Special Protocol Assessment (SPA) for the Phase 3b NurOwn trial design.

regulatory action
80%
bearishMay 15

Heavy reliance on convertible notes with high interest and deep discounts creates significant dilution risk.

dilution risk
90%
bullishMay 15

Net loss reduced by 26% year-over-year through aggressive cost cutting in R&D and G&A.

margin expansion
60%
neutralMay 15

Raised $1.25 million in Q1 2026 via private placements and short-term loans to sustain operations.

capital raise
50%
bullishMay 15

FDA granted Special Protocol Assessment (SPA) for the Phase 3b NurOwn trial design.

regulatory action
80%
bearishMay 15

Heavy reliance on convertible notes with high interest and deep discounts creates significant dilution risk.

dilution risk
90%
bullishMar 31

FDA granted Special Protocol Assessment (SPA) for Phase 3b trial design.

regulatory action
80%
bearishMar 31

Critical cash shortage and reliance on high-interest convertible debt.

capital raise
90%
neutralMar 31

Implementation of strategic cash compensation deferrals for leadership.

management change
40%

Filing History

8-KMay 28, 2026

The appointment of Peter Pitts represents a calculated effort by Brainstorm Cell Therapeutics to bridge the gap between clinical development and regulatory approval. By expanding the board to eight members and integrating a former FDA insider, BCLI is signaling to the market that it is prioritizing regulatory execution. The overall impact of the filing is a shift in the company's risk profile, moving from a purely developmental stage to one with enhanced institutional knowledge of the FDA's expectations, though investors remain focused on whether this governance upgrade will translate into tangible clinical milestones.

10-QMay 15, 2026

The latest 10-Q reveals a company at a critical crossroads, balancing a validated regulatory blueprint against a deteriorating financial foundation. While the SPA agreement provides a clear roadmap for the Phase 3b trial, the company's ability to actually execute that trial remains tethered to its capacity to raise capital in a distressed environment. The shift to the OTCQB market has further constrained liquidity and visibility. Investors are essentially weighing the binary outcome of the NurOwn platform's efficacy against the immediate risk of insolvency or extreme dilution. The narrowing of operating losses is a positive signal of management's attempt to extend the runway, but the reliance on predatory-style financing suggests that the cost of survival may be prohibitively high for current equity holders.

10-KMar 31, 2026

The 10-K reveals a high-stakes binary event centered on the Phase 3b trial. While the company has successfully 'cleaned the slate' with the FDA via the SPA and CMC alignment, it is doing so from a position of extreme financial fragility. The tension between the technical progress of the NurOwn platform and the deteriorating balance sheet creates a volatile risk-reward profile for investors. Ultimately, the filing highlights a company that has weaponized its remaining resources to reach a definitive clinical readout. The outcome will likely be a total re-rating of the company: either a validation of the exosome platform that attracts the necessary institutional capital to scale, or a final collapse under the weight of its debt and the historical skepticism of the FDA.